Skip to main content

Advertisement

SpringerLink
Log in

HER-2/neu is an independent prognostic factor in type I endometrial adenocarcinoma

  • Gynecologic Oncology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Purpose

Το define the prognostic significance of HER-2/neu and PTEN expression in patients with endometrioid (type I) endometrial cancer.

Methods

Seventy-seven patients with endometrioid endometrial carcinoma were included in the study, in a period between 1996 and 2009. Patients with coexisting malignancy and those having incomplete immunohistochemical data or clinical follow-up were excluded. Histological staging was defined according to the revised FIGO staging (2009). Clinico-pathologic and immunohistochemical characteristics were correlated in a multivariate Cox regression analysis with overall survival (OS), cancer-related survival (CRS) and disease-free survival (DFS).

Results

Mean age of the patients was 62.7 years. The median follow-up was 67 months (9–124 months). HER-2/neu expression was detected in 18.2 % (n = 14), and PTEN expression in 72.7 % (n = 56) of our patients. Multivariate Cox regression analysis showed that patient’s age, FIGO staging and HER-2/neu expression were independent prognostic factors for OS, CRS and DFS. PTEN expression did not significantly affect survival outcomes of the present study.

Conclusions

HER-2/neu but not PTEN expression is an independent prognostic factor for type I endometrial carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Engelsen IB, Stefansson IM, Beroukhim R, Sellers WR, Meyerson M, Akslen LA, Salvesen HB (2008) HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. Int J Oncol 32:307–316

    CAS  PubMed  Google Scholar 

  2. Bąkiewicz A, Michalak J, Sporny S (2010) Immunoexpression and clinical significance of the PTEN and MLH1 proteins in endometrial carcinomas. Pol J Pathol 61:185–191

    PubMed  Google Scholar 

  3. Grushko TA, Filiaci VL, Mundt AJ, Ridderstråle K, Olopade OI, Fleming GF (2008) Gynecologic oncology group. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol 108:3–9 Epub 2007 Oct 18

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Bansal N, Yendluri V, Wenham RM (2009) The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 16:8–13

    PubMed  Google Scholar 

  5. Papanikolaou A, Kalogiannidis I, Goutzioulis M, Misailidou D, Makedos A, Vergote I, Makedos G (2006) Pelvic lymphadenectomy as alternative to postoperative radiotherapy in high risk early stage endometrial cancer. Arch Gynecol Obstet 274:91–96

    Article  CAS  PubMed  Google Scholar 

  6. Creasman W (2009) Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet 105:109

    Article  PubMed  Google Scholar 

  7. Ayhan A, Taskiran C, Yuce K, Kucukali T (2002) The prognostic value of nuclear grading and the revised FIGO grading of endometrial adenocarcinoma. Int J Gynecol Pathol 22:71–74

    Article  Google Scholar 

  8. Coronado PJ, Vidart JA, Lopez-asenjo JA, Fasero M, Furio-bacete V, Magrina J, Escudero M (2001) P53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression. Eur J Obstet Gynecol Reprod Biol 98:103–108

    Article  CAS  PubMed  Google Scholar 

  9. Ryan AJ, Susil B, Jobling TW, Oehler MK (2005) Endometrial cancer. Cell Tissue Res 322:53–61

    Article  PubMed  Google Scholar 

  10. Rolitsky CD, Theil KS, McGaughy VR, Copeland LJ, Niemann TH (1999) HER-2/neu amplification and overexpression in endometrial carcinoma. Int J Gynecol Pathol 18:138–143

    Article  CAS  PubMed  Google Scholar 

  11. Benevolo M, Vocaturo A, Novelli F, Mariani L, Vocaturo G, Cianciulli AM et al (2007) Prognostic value of HER2 and progesterone receptor expression in endometrial carcinoma with positive peritoneal washing. Anticancer Res 27:2839–2844

    CAS  PubMed  Google Scholar 

  12. Srijaipracharoen S, Tangjitgamol S, Tanvanich S, Manusirivithaya S, Khunnarong J, Thavaramara T et al (2010) Expression of ER, PR, and HER-2/neu in endometrial cancer: a clinicopathological study. Asian Pac J Cancer Prev 11:215–220

    PubMed  Google Scholar 

  13. Jongen VH, Briët JM, de Jong RA, Joppe E, ten Hoor KA, Boezen HM, Evans DB, Hollema H, van der Zee AG (2009) Nijman HW aromatase, cyclooxygenase 2, HER-2/neu, and p53 as prognostic factors in endometrioid endometrial cancer. Int J Gynecol Cancer 19:670–676

    Article  PubMed  Google Scholar 

  14. Latta E, Chapman WB (2002) PTEN mutations and evolving concepts in endometrial neoplasia. Curr Opin Obstet Gynecol 14:59–65

    Article  PubMed  Google Scholar 

  15. Yao YY, Xu WZ, Wang Y, Shen DH, Wang JL, Wei LH (2011) Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma. Beijing Da Xue Xue Bao 43:743–748

    CAS  PubMed  Google Scholar 

  16. Inaba F, Kawamata H, Teramoto T, Fukasawa I, Inaba N, Fujimori T (2005) PTEN and p53 abnormalities are indicative and predictive factors for endometrial carcinoma. Oncol Rep 13:17–24

    CAS  PubMed  Google Scholar 

  17. Kanamori Y, Kigawa J, Itamochi H, Sultana H, Suzuki M, Ohwada M et al (2002) PTEN expression is associated with prognosis for patients with advanced endometrial carcinoma undergoing postoperative chemotherapy. Int J Cancer 100:686–689

    Article  CAS  PubMed  Google Scholar 

  18. Athanassiadou P, Athanassiades P, Grapsa D, Gonidi M, Athanassiadou AM, Stamati PN, Patsouris E (2007) The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: a prospective immunocytochemical study. Int J Gynecol Cancer 17:697–704

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

Authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. 4th Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, Konstantinoupoleos 49, 56224, Thessaloníki, Greece

    Ioannis Kalogiannidis, Stamatios Petousis, Chrysoula Margioula-Siarkou & Theodoros Agorastos

  2. Department of Pathology, Aristotle University of Thessaloniki, Thessaloníki, Greece

    Mattheos Bobos

  3. Department of Radiotherapy, General Hospital “Papageorgiou”, Thessaloníki, Greece

    Maria Topalidou

  4. 1st Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, Thessaloníki, Greece

    Alexis Papanikolaou

  5. Division of Gynaecologic Oncology, Department of Obstetrics and Gynaecology, Leuven Cancer Institute, University Hospitals Leuven, Katholieke Universiteit Leuven, Leuven, Belgium

    Ignace Vergote

Authors
  1. Ioannis Kalogiannidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stamatios Petousis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mattheos Bobos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chrysoula Margioula-Siarkou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maria Topalidou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alexis Papanikolaou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ignace Vergote
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Theodoros Agorastos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stamatios Petousis.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kalogiannidis, I., Petousis, S., Bobos, M. et al. HER-2/neu is an independent prognostic factor in type I endometrial adenocarcinoma. Arch Gynecol Obstet 290, 1231–1237 (2014). https://doi.org/10.1007/s00404-014-3333-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-014-3333-2

Keywords

Search

Navigation